Effect of cytokines, dexamethazone and the A/T-signal peptide polymorphism on the expression of alpha1-antichymotrypsin in astrocytes: significance for Alzheimer's disease

This publication has 59 references indexed in Scilit:

• The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alphal-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IκB-alpha
  Neuropharmacology, 1999
• Association of α1‐antichymotrypsin polymorphism with cerebral amyloid angiopathy
  Annals of Neurology, 1998
• ?1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E ?4 allele carriers
  Annals of Neurology, 1997
• A specific structural interaction of Alzheimer's peptide Aβ1–42 with α1-antichymotrypsin
  Nature Structural & Molecular Biology, 1996
• IL-1β and TNFα, but not IL-6, induce α1- antichymotrypsin expression in the human astrocytoma cell line U373 MG
  NeuroReport, 1995
• Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia
  Neurobiology of Aging, 1995
• Rat Contrapsins Are the Type II Acute Phase Proteins: Regulation by Interleukin 6 on the mRNA Level
  Biochemical and Biophysical Research Communications, 1994
• The acute phase response
  Immunology Today, 1994
• The Involvement of Proteases, Protease Inhibitors, and an Acute Phase Response in Alzheimer's Disease
  Annals of the New York Academy of Sciences, 1992
• A highly sensitive northern blot assay detects multiple proenkephalin a-like mRNAs in human caudate nucleus and pheochromocytoma
  Bioscience Reports, 1988